Drug: Mircera
Indication: Anemia
Company: Roche
Approval Date: November 14, 2007
Scoop: Mircera has a longer half-life than other commercially available erythropoiesis-stimulating agents (ESA). However, Roche lost a patent infringement case to Amgen, which markets the bestselling--and controversial--anti-anemia drugs Aranesp and Epogen. Though Mircera is available overseas, for the forseeable future it will not be marketed in the U.S.
More news:
Mircera gets FDA nod, but blocked by patent case. Report [1]
Roche: Patent ruling won't stop Mircera. Report [2]
Roche to Launch Mircera in UK and Germany. Report [2]
Links:
[1] http://www.fiercebiotech.com/story/mircera-gets-fda-nod-blocked-patent-case/2007-11-15
[2] http://www.fiercepharma.com/story/roche-patent-ruling-stop-mircera/2007-08-29
[3] http://www.fiercebiotech.com/special-reports/tasigna-2007-fda-approvals
[4] http://www.fiercebiotech.com/special-reports/2007-fda-approvals
[5] http://www.fiercebiotech.com/special-reports/kuvan-2007-fda-approvals